Pharmacologic reversal of epigenetic silencing of the anticancer protein BRM: a novel targeted treatment strategy
Open Access
- 11 April 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 30 (29), 3289-3294
- https://doi.org/10.1038/onc.2011.80
Abstract
Tumor suppressor genes and oncogenes are both commonly altered during carcinogenesis. For oncogenes and other genes that drive growth, targeting mutated or activated forms (such as the EGFR-Her2/Nneu pathway) has been shown to be an effective anti-cancer approach. Pharmacologically targeting tumor suppressor genes has not been as fruitful, as many tumor suppressor genes are irreversibly silenced through somatic mutation or entirely deleted during carcinogenesis, thereby making it difficult to restore gene function. BRM, a key SWI/SNF complex subunit and a putative tumor suppressor gene, is inactivated in 15–20% of many solid tumor types. Unlike other tumor suppressor genes, the loss of BRM has been shown to be a reversible epigenetic change, rather than an irreversible genetic alteration. Using a high throughput drug screen, we identified a number of compounds that could effectively restore BRM expression and function. Two of these compounds, RH (RH02032) and GK (GK0037), were found to be such reactivating agents. Both compounds led to robust re-expression of BRM, induced downstream expression of BRM-dependent genes and inhibited BRM-dependent growth across a wide range of BRM-deficient cancer cell lines of different origins. We therefore show, for the first time, that pharmacologic reversal of epigenetic changes of the SWI/SNF chromatic remodeling complex subunit, BRM, is a potentially viable and novel therapeutic approach.Keywords
This publication has 67 references indexed in Scilit:
- Panhistone deacetylase inhibitors inhibit proinflammatory signaling pathways to ameliorate interleukin-18-induced cardiac hypertrophyPhysiological Genomics, 2011
- Pyrimidine biosynthesis links mitochondrial respiration to the p53 pathwayProceedings of the National Academy of Sciences of the United States of America, 2010
- Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen speciesProceedings of the National Academy of Sciences, 2010
- Chemical phylogenetics of histone deacetylasesNature Chemical Biology, 2010
- Genome-wide Mapping of HATs and HDACs Reveals Distinct Functions in Active and Inactive GenesCell, 2009
- The SWI/SNF complex and cancerOncogene, 2009
- Lysine Acetylation: Codified Crosstalk with Other Posttranslational ModificationsMolecular Cell, 2008
- Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell linesHuman Mutation, 2008
- Differential regulation and properties of MAPKsOncogene, 2007
- Histone acetyltransferase complexes: one size doesn't fit allNature Reviews Molecular Cell Biology, 2007